Nebu-Flow secures £4.7m to advance respiratory drug delivery technology
The financing round was led by SCVC with participation from a group of institutional investors and agencies.
Nebu-Flow develops an advanced nebuliser platform designed to improve respiratory drug delivery and handle complex formulations.
Nebu-Flow has secured £4.7m in a new funding round to advance its respiratory drug delivery technology. The capital will support the company as it prepares for the commercialisation stage and moves towards delivering RNA-based formulations via inhalation.
The investment was led by SCVC, with participation from Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund. The firm has developed a proprietary nebuliser platform that generates precise droplets suited for peripheral and systemic inhalation.
Investor perspective
"We are deeply impressed by the team's achievement of its technical and commercial milestones to date, demonstrating their capability and readiness for the next phase in healthcare innovation. This investment underscores our confidence in Nebu-Flow's groundbreaking nebulization technology, which is poised to transform respiratory drug delivery, improve health and deliver impact."
Harry Destecroix
Founder, Science Creates Ventures
Use of funds
- 01Continue product development
-20webclip.png)
